Leukemia & Lymphoma Society of Canada
Toronto, ON M2J 4P8
President & CEO: Louis J. DeGennaro
Board Chair: Gilles Legault
Charitable Reg. #: 10762 3654 RR0001
Grade: B-The grade is based on the charity's public reporting of the work it does and the results it achieves.
Need for Funding
Full-time staff #53
Avg. Compensation $80,162
Top 10 Staff Salary Range
|$300k - $350k||0|
|$250k - $300k||0|
|$200k - $250k||1|
|$160k - $200k||1|
|$120k - $160k||1|
|$80k - $120k||7|
|$40k - $80k||0|
About Leukemia & Lymphoma Society of Canada:
The Leukemia & Lymphoma Society of Canada (LLSC) was founded in 1955. The charity works to find cures for all forms of blood cancer and improve the quality of life of patients and their families. To achieve its mission, the LLSC has three main programs: research, patient support services, and education services. Both research and educational programming were 38% of program costs in 2015, while patient support programming was 25%.
The Leukemia & Lymphoma Society of Canada has established partnerships with various organizations to propel its programs, including a long-standing partnership with United Food and Commercial Workers (UFCW). The UFCW runs fundraising events to provide funds for the LLSC’s research, patient support and educational programs.
The Leukemia & Lymphoma Society of Canada’s research programs provide grants for a total of 28 Canadian research projects annually. These projects investigate new treatments and possible cures for blood cancers. The Therapy Acceleration Program (TAP) accounts for a large portion of LLSC research funding. This program funds clinical research projects run by companies that focus on improving the quality of care that blood cancer patients receive. One company that received funding from TAP is Celator Pharmaceuticals. The company is developing a drug called VYXEOS, designed to improve the survival rate of patients living with acute myeloid leukemia (AML). In May 2016, clinical trial results showed that the drug significantly improves the survival rate of AML patients.
The First Connection Program is one of the patient services programs offered by LLSC. The program connects patients at any stage of diagnosis with a volunteer who has gone through the same challenges of living with blood cancer – the LLSC website reports that over 300 matches are available for patients. The LLSC also runs Family Support Groups that provide patients and their families with a place to share information, support, knowledge and feelings in a friendly environment. There are currently 15 groups stationed across Canada.
With donations of $13.2m in F2015, the Leukemia & Lymphoma Society of Canada is a ‘big-cap’ charity. Administrative costs are 10% of revenues and fundraising costs are 32% of donations. Combined, this falls outside Ci’s reasonable range for overhead spending, with $0.42 of every donated dollar being used to cover overhead expenses. The Canadian average is $0.26.
LLSC’s funding reserves of $6.9m (of which $1.9m are donor-endowed) cover 94% of annual program costs. When donor-endowed funds are omitted, LLSC’s funding reserves cover 69% of annual program costs.
This charity report is an update that is currently being reviewed by LLSC. Changes and edits may be forthcoming.
Updated on June 3, 2016 by Katie Khodawandi.
Financial RatiosFiscal year ending June
|Administrative costs as % of revenues||10.0%||9.6%||7.6%|
|Fundraising costs as % of donations||31.5%||39.6%||34.8%|
|Program cost coverage (%)||94.2%||71.2%||52.9%|
Summary Financial StatementsAll figures in $000s
|Cash flow from operations||761||441||504|